Current Report Filing (8-k)
21 6월 2018 - 1:51AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 20, 2018 (June 16, 2018)
LUCKWEL
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Nevada
|
|
333-187874
|
|
46-1660653
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
One International
Place, Suite 1400, Boston
|
|
MA 02110
|
(Address of principal
executive offices)
|
|
(Zip Code)
|
Registrant’s
telephone number, include area code
+1(617) 335 7788
11757
Katy Freeway, Suite 1300-A, Houston, Texas 77079
.
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
1.01 Entry into a Material Definitive Agreement
On
June 16, 2018, Luckwel Pharmaceuticals Inc. (the “Company”) entered into a virtual office service agreement with Servcorp
Limited (the “Agreement”), pursuant to which the Company leased an office space located at Suite 1400, Boston, MA
02110. The lease under the Agreement started on June 16, 2018 and is on a month to month basis for which the Company pays a monthly
rent of $299.
This
description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the form of Agreement,
a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
LUCKWEL
PHARMACEUTICALS INC.
|
|
|
|
Date:
|
June
20, 2018
|
|
/s/
Kingrich Lee
|
|
|
Name:
|
Kingrich
Lee
|
|
|
Title:
|
Chief
Executive Officer and Chief Financial Officer
|
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Luckwel Pharmaceuticals (GM) (USOTC:LWEL)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
Luckwel Pharmaceuticals Inc (GM) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Luckwel Pharmaceuticals Inc. News Articles